Ajay Major, MD
Hematology & Oncology · Aurora, CONPI 1336502731
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,803 of the $24,246 with a category attached, or 94.0%. 9 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 49.2% of the total. 2025 is the largest year on record at $23,950, more than ten times the $131 reported in 2022.
Across 26 payments — averaging $932.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$12K
- Genentech, Inc.$8K
- Gilead$3K
- Bristol Myers Squibb$981
- AbbVie$131
- Beone Medicines USA, Inc.$131
- plus $200 from 3 others
Across 45 payments — averaging $6582.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$248K
- GSK$43K
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$22,80394%
- Travel & lodging$8844%
- Food & beverage$5602%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $11,938 |
| Genentech, Inc. | 5 | $7,500 |
| Gilead | 2 | $3,365 |
| Bristol Myers Squibb | 8 | $981 |
| AbbVie | 6 | $131 |
| Beone Medicines USA, Inc. | 1 | $131 |
| Karyopharm Therapeutics Inc. | 1 | $131 |
| Genmab U.S., Inc. | 1 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,246 in reported general payments places this provider in the 80th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 21 | $260,251 |
| Acyclovir | 19 | $363 |
| Oxycodone Hcl | 14 | $304 |
| Prochlorperazine Maleate | 13 | $137 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $126 |
| Levofloxacin | 12 | $69 |
| Prednisone | 19 | $38 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.